Key clinical point: A combination of rituximab and vemurafenib offers a high complete remission rate among patients with relapsed or refractory hairy cell leukemia (HCL).
Major finding: Complete remission was achieved in 96% of evaluable patients who received the combination.
Study details: A phase 2 trial involving 31 patients with relapsed or refractory HCL.
Disclosures: Dr. Tiacci reported financial relationships with Roche, AbbVie, and Shire.
Tiacci E et al. EHA Congress, Abstract S104.